Biontech SE
BNTX99.710USD
+3.170+3.28%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
23.98BMarket Cap
LossP/E TTM
More Details of Biontech SE Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Biontech SE Info
Ticker SymbolBNTX
Company nameBiontech SE
IPO dateOct 10, 2019
CEOProf. Ugur Sahin, M.D.
Number of employees6772
Security typeDepository Receipt
Fiscal year-endOct 10
AddressAn der Goldgrube 12
CityMAINZ
Stock exchangeNASDAQ Global Select Consolidated
CountryGermany
Postal code55131
Phone4949613190840
Websitehttps://www.biontech.com/
Ticker SymbolBNTX
IPO dateOct 10, 2019
CEOProf. Ugur Sahin, M.D.
Company Executives of Biontech SE
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ms. Annemarie Hanekamp
Ms. Annemarie Hanekamp
Member of the Management Board, Chief Commercial Officer
Member of the Management Board, Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Ramon Zapata Gomez
Mr. Ramon Zapata Gomez
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 12
Currency: USDUpdated: Wed, Mar 12
FY2019
FY2018
FY2017
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
Other
33.60%
Shareholders
Shareholders
Proportion
AT Impf GmbH
42.36%
Medine GmbH
16.69%
Baillie Gifford & Co.
3.28%
Fidelity Management & Research Company LLC
2.07%
T. Rowe Price Investment Management, Inc.
2.01%
Other
33.60%
Shareholder Types
Shareholders
Proportion
Corporation
59.74%
Investment Advisor
15.59%
Investment Advisor/Hedge Fund
3.82%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
Other
15.49%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
793
55.39M
23.04%
-2.63M
2025Q2
815
205.26M
85.38%
-4.32M
2025Q1
851
205.71M
85.57%
-4.55M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AT Impf GmbH
101.85M
42.37%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
16.69%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
8.04M
3.34%
-120.81K
-1.48%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.98M
2.9%
+1.02M
+17.22%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
3.60M
1.5%
+3.51M
+4076.79%
Jun 30, 2025
Flossbach von Storch AG
4.23M
1.76%
-29.53K
-0.69%
Jun 30, 2025
PRIMECAP Management Company
4.00M
1.66%
-44.96K
-1.11%
Jun 30, 2025
Dodge & Cox
877.44K
0.36%
+877.44K
--
Jun 30, 2025
Sahin (Ugur MD)
2.05M
0.85%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
3.66M
1.52%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Langar Global HealthTech ETF
3.74%
iShares Genomics Immunology and Healthcare ETF
3.63%
Global X Genomics & Biotechnology ETF
3.06%
First Trust NYSE Arca Biotechnology Index Fund
2.71%
VanEck Biotech ETF
2.39%
Franklin Genomic Advancements ETF
2.28%
Virtus LifeSci Biotech Products ETF
1.57%
WisdomTree BioRevolution Fund
1.43%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1%
View more
Langar Global HealthTech ETF
Proportion3.74%
iShares Genomics Immunology and Healthcare ETF
Proportion3.63%
Global X Genomics & Biotechnology ETF
Proportion3.06%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.71%
VanEck Biotech ETF
Proportion2.39%
Franklin Genomic Advancements ETF
Proportion2.28%
Virtus LifeSci Biotech Products ETF
Proportion1.57%
WisdomTree BioRevolution Fund
Proportion1.43%
ProShares Ultra Nasdaq Biotechnology
Proportion1.02%
Invesco Nasdaq Biotechnology ETF
Proportion1%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Biontech SE?
The top five shareholders of Biontech SE are:
AT Impf GmbH holds 101.85M shares, accounting for 42.37% of the total shares.
Medine GmbH holds 40.13M shares, accounting for 16.69% of the total shares.
Baillie Gifford & Co. holds 8.04M shares, accounting for 3.34% of the total shares.
Fidelity Management & Research Company LLC holds 6.98M shares, accounting for 2.90% of the total shares.
T. Rowe Price Investment Management, Inc. holds 3.60M shares, accounting for 1.50% of the total shares.
AT Impf GmbH holds 101.85M shares, accounting for 42.37% of the total shares.
Medine GmbH holds 40.13M shares, accounting for 16.69% of the total shares.
Baillie Gifford & Co. holds 8.04M shares, accounting for 3.34% of the total shares.
Fidelity Management & Research Company LLC holds 6.98M shares, accounting for 2.90% of the total shares.
T. Rowe Price Investment Management, Inc. holds 3.60M shares, accounting for 1.50% of the total shares.
What are the top three shareholder types of Biontech SE?
The top three shareholder types of Biontech SE are:
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
How many institutions hold shares of Biontech SE (BNTX)?
As of 2025Q3, 793 institutions hold shares of Biontech SE, with a combined market value of approximately 55.39M, accounting for 23.04% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -62.34%.
What is the biggest source of revenue for Biontech SE?
In FY2019, the Collaboration Revenue business generated the highest revenue for Biontech SE, amounting to 84.43M and accounting for 77.75% of total revenue.
